STAMFORD, Conn., June 21, 2018 /PRNewswire-PRWeb/ -- As part of its ambitious mission to accelerate Lyme and tick-borne
"As the problem of Lyme disease continues to escalate, we are committed to funding the most innovative and promising Lyme and tick-borne disease research science," said Scott Santarella, GLA's CEO. "We are working diligently to accelerate Lyme knowledge by funding top researchers, innovative ideas, and results-driven efforts for the benefits of all Lyme disease patients and their families."
With an unrivaled focus on the science of Lyme, GLA recently issued its inaugural research report, a first for any Lyme disease organization in the nation. The 42-page report covers all research activities undertaken by GLA and its predecessor organizations—Lyme Research Alliance and Tick-Borne Disease Alliance—to become the largest 501(c)(3) funder of Lyme and tick-borne diseases research in existence. The report outlines GLA's role as an early-stage funder of numerous firsts in the Lyme research world to benefit patients, and how GLA-funded researchers have advanced from GLA seed funding to significant support from the National Institutes of Health (NIH) and other major funding institutions.
"GLA's mission is to find answers to Lyme disease's myriad unknowns," said Santarella. "We are at the forefront of discovery and innovation thus making us a catalyst for change across the Lyme disease world."
In collaboration with GLA-funded scientists, GLA has achieved many evidence-based accomplishments. It has empirically proven that 10 to 20% of Lyme patients do not respond to early antibiotic therapy; identified new and better targets for treatment; mapped the genome of the bacterium that causes Lyme, and explored drug combinations that successfully attack "persister" cells that evade conventional antibiotics, as well as antibiotic resistant Lyme bacteria. All of GLA-funded research projects—100%— have been published in peer-reviewed scientific journals such as Journal of Immunology, Emerging Microbes & Infections and PLoS ONE.
GLA awarded close to $2 million in research grants this year alone to 15 researchers at leading academic and medical institutions across the country. Those awarded 2017-18 research grants are:
GLA's researchers are selected following a rigorous process using guidelines established by the NIH. Each grant proposal is evaluated by GLA's highly regarded Scientific Advisory Board and must meet the same scientific standards that the NIH applies to its own research grant review process. GLA's in-house Chief Scientific Officer and its Director of Research and Science, both Ph.Ds, help oversee the grantees, Santarella said, making GLA dedicated and committed stewards of donor dollars. Moreover, GLA grants are awarded to projects judged to have exceptional prospects of delivering measurable advances.
Lyme disease is a growing epidemic with more than 329,000 reported new cases each year in the United States, according to the Centers for Disease Control and Prevention. However, there are presently no accurate diagnostic tests, no standard treatment, and no cure.
GLA is now accepting grant proposals for its 2018-19 grant funding cycle. All applications are due by August 1, 2018 midnight EST. Award decisions will be announced in January 2019. For more information, go to GLA.org.
### ABOUT GLOBAL LYME ALLIANCE Global Lyme Alliance (GLA) is the leading 501(c)(3) dedicated to conquering Lyme disease through research, education and awareness. GLA has gained national prominence for funding the most urgent and promising research in the field, while expanding education and awareness programs for the general public and physicians. Learn more at GLA.org.
SOURCE Global Lyme Alliance
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All